Affitech Exploits Antibody Discovery Platforms: CBAS and MBAS Approaches Generate Drugs for Collaborations and In-house Pipeline

摘要

Antibodies now account for about one-quarter of the biopharmaceutical market and the sector is growing at 30-35% per annum. Meanwhile, there has been a recent wave of mergers and acquisitions of antibody companies by big pharma and biotech firms (e.g., Cambridge Antibody Technology's and Medlmmune's acquisition by AstraZeneca as well as Tanox' acquisition by Genentech). Affitech (www.affitech.com) is a well-established biotech company based in Oslo, specializing in the discovery and development of fully human recombinant therapeutic antibodies for cancer and other potential applications," says Rathin Das, Ph.D., svp, CBO, and president.